Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Convatec shares slump on wound care uncertainty
(Sharecast News) - Shares in medtech group Convatec slumped on Thursday despite the company keeping its top-level guidance for 2024, though growth forecasts in the Advanced Wound Care division have been reduced due to "short-term uncertainty". The company said it is still on track to deliver organic group revenue growth of between 5% and 7% in 2024.
Growth forecasts for Ostomy Care and Infusion Care remain unchanged, while Continence Care expectations have increased to mid to high single-digit percentage growth (from mid single-digit guidance in March) due to a more positive performance in the first quarter.
However, Advanced Wound Care revenues are now expected to grow by mid to high-single digits (down from high single-digit guidance previously), which it ascribes to uncertainty arising from draft proposed local coverage determinations (LCDs) which could affect its InnovaMatrix product, which generated $74m in sales last year.
InnovaMatrix launched in the US in early 2022 as the first porcine placental-derived extra cellular matrix device, to manage wounds like diabetic foot ulcers, venuous leg ulcers and trauma wounds.
However, draft proposed LCDs published by seven Medicare Administrative Contractors in April relating to the use of products to treat diabetic foot ulcers and venous leg ulcers did not include InnovaMatrix on the covered list, despite it meeting technical requirements and being approved for use by the FDA. This, Convatec says, was due to its recent entry to the market and the timeline necessary to generate and to publish clinical evidence.
"We are actively engaging with all relevant parties during the 45-day consultation window, which may lead to different outcomes than the current draft proposal. Convatec firmly believes that InnovaMatrix® delivers strong clinical outcomes for patients and choice for health care practitioners," the company said on Thursday.
Shares were down 4.2% at 255p by 0850 BST.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.